Health Care [ 11/12 ] | Biotechnology [ 68/75 ]
NASDAQ | Common Stock
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2.
It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics.
The company was incorporated in 1989 and is based in Carlsbad, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 1, 24 | -0.45 Increased by +25.00% | -0.92 Increased by +51.09% |
| May 7, 24 | -0.98 Decreased by -12.64% | -1.05 Increased by +6.67% |
| Feb 21, 24 | -0.06 Increased by +95.59% | -0.83 Increased by +92.77% |
| Nov 2, 23 | -1.03 Decreased by -212.12% | -1.04 Increased by +0.96% |
| Aug 9, 23 | -0.60 Increased by +18.92% | -0.90 Increased by +33.33% |
| May 3, 23 | -0.87 Decreased by -89.13% | -0.91 Increased by +4.40% |
| Feb 22, 23 | -1.36 Decreased by -196.45% | -0.92 Decreased by -47.83% |
| Nov 9, 22 | -0.33 Increased by +43.10% | -0.74 Increased by +55.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 119.50 M Decreased by -8.78% | -142.80 M Decreased by -15.16% | Decreased by -119.50% Decreased by -26.25% |
| Dec 31, 23 | 324.50 M Increased by +113.49% | -9.26 M Increased by +82.19% | Decreased by -2.85% Increased by +91.66% |
| Sep 30, 23 | 144.00 M Decreased by -9.87% | -147.00 M Decreased by -212.82% | Decreased by -102.08% Decreased by -247.07% |
| Jun 30, 23 | 188.00 M Increased by +40.52% | -85.00 M Increased by +19.15% | Decreased by -45.21% Increased by +42.46% |
| Mar 31, 23 | 131.00 M Decreased by -7.69% | -124.00 M Decreased by -90.29% | Decreased by -94.66% Decreased by -106.15% |
| Dec 31, 22 | 152.00 M Decreased by -65.45% | -52.00 M Decreased by -123.11% | Decreased by -34.21% Decreased by -166.90% |
| Sep 30, 22 | 159.77 M Increased by +20.04% | -46.99 M Increased by +43.02% | Decreased by -29.41% Increased by +52.53% |
| Jun 30, 22 | 133.79 M Increased by +6.39% | -105.14 M Decreased by -30.00% | Decreased by -78.58% Decreased by -22.18% |